Cargando…

Improved NYVAC-Based Vaccine Vectors

While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) have been encouraging and suggest that further improvements of the prime/boost vaccine combination of a poxvirus and protein are needed. With this aim, in this investigation we have generated derivativ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kibler, Karen V., Gomez, Carmen E., Perdiguero, Beatriz, Wong, Shukmei, Huynh, Trung, Holechek, Susan, Arndt, William, Jimenez, Victoria, Gonzalez-Sanz, Ruben, Denzler, Karen, Haddad, Elias K., Wagner, Ralf, Sékaly, Rafick P., Tartaglia, James, Pantaleo, Giuseppe, Jacobs, Bertram L., Esteban, Mariano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212513/ https://www.ncbi.nlm.nih.gov/pubmed/22096477 http://dx.doi.org/10.1371/journal.pone.0025674

Ejemplares similares

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors
por: Quakkelaar, Esther D., et al.
Publicado: (2011)

Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”
por: Kibler, Karen V., et al.
Publicado: (2019)

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
por: Gómez, Carmen Elena, et al.
Publicado: (2017)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C
por: Perdiguero, Beatriz, et al.
Publicado: (2013)

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
por: Harari, Alexandre, et al.
Publicado: (2008)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
por: Perdiguero, Beatriz, et al.
Publicado: (2022)

Characterization of the Physiological Response following In Vivo Administration of Astragalus membranaceus
por: Denzler, Karen, et al.
Publicado: (2016)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
por: Bart, P, et al.
Publicado: (2012)

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles
por: Meador, Lydia R., et al.
Publicado: (2017)

Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques
por: Denzler, Karen L., et al.
Publicado: (2011)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus
por: Arndt, William D., et al.
Publicado: (2016)

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens
por: Nájera, José Luis, et al.
Publicado: (2010)

Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses
por: Holechek, Susan A., et al.
Publicado: (2013)

P17-23. Enhanced expression of HIV antigens and improved antigen presentation after infection with replication competent attenuated vaccinia virus in vitro
por: Quakkelaar, E, et al.
Publicado: (2009)

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
por: Sekaly, Rafick-Pierre
Publicado: (2008)

Regulation of Inflammatory Gene Expression in PBMCs by Immunostimulatory Botanicals
por: Denzler, Karen L., et al.
Publicado: (2010)

P17-07. Insertion of a vaccinia virus host range (hr) gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
por: Najera, JL, et al.
Publicado: (2009)

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial
por: Lévy, Yves, et al.
Publicado: (2020)

Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses
por: Hulot, SL, et al.
Publicado: (2012)

Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax
por: Midgley, Claire M., et al.
Publicado: (2008)

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens
por: Perdiguero, Beatriz, et al.
Publicado: (2012)

In Vitro Characterization of a Nineteenth-Century Therapy for Smallpox
por: Arndt, William, et al.
Publicado: (2012)

A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology
por: Liu, Jie, et al.
Publicado: (2016)

Small Hero with Great Powers: Vaccinia Virus E3 Protein and Evasion of the Type I IFN Response
por: Szczerba, Mateusz, et al.
Publicado: (2022)

Paracrine Transfer of Mouse Mammary Tumor Virus Superantigen
por: Delcourt, Marc, et al.
Publicado: (1997)

Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines
por: Pelletier, Adam N, et al.
Publicado: (2022)

Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
por: Gómez, Carmen Elena, et al.
Publicado: (2021)

Follicular CD4 T Helper Cells As a Major HIV Reservoir Compartment: A Molecular Perspective
por: Aid, Malika, et al.
Publicado: (2018)

Early Activation of Caspases during T Lymphocyte Stimulation Results in Selective Substrate Cleavage in Nonapoptotic Cells
por: Alam, Antoine, et al.
Publicado: (1999)

Highly Biased CDR3 Usage in Restricted Sets of β Chain Variable Regions During Viral Superantigen 9 Response
por: Ciurli, Cristina, et al.
Publicado: (1998)

A systems framework for vaccine design
por: Mooney, Michael, et al.
Publicado: (2013)

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C
por: Gómez, C, et al.
Publicado: (2012)

Myeloid Cells Enriched for a Dendritic Cell Population From People Living With HIV Have Altered Gene Expression Not Restored by Antiretroviral Therapy
por: Murray, Shannon M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_usnn9nf347cf7spmt8sdibcvt2